April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Long-term Efficacy and Safety of Dexamethasone Intravitreal Implant in Phakic and Pseudophakic Eyes with Diabetic Macular Edema
Author Affiliations & Notes
  • Young Hee Yoon
    Asan Medical Center, Ophthalmology, Univ of Ulsan, College of Med, Seoul, Republic of Korea
  • David S Boyer
    Retina-Vitreous Associates Medical Group, Los Angeles, CA
  • Rubens Belfort, Jr.
    Vision Institute, Federal University of São Paulo, São Paulo, Brazil
  • Francesco Bandello
    Hospital San Raffaele, University Vita Salute, Milan, Italy
  • Raj K Maturi
    Midwest Eye Institute, Indianapolis, IN
  • Albert J Augustin
    Ophthalmology, Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany
  • Xiao-Yan Li
    Allergan, Inc., Irvine, CA
  • Harry Cui
    Allergan, Inc., Irvine, CA
  • Yehia Hashad
    Allergan, Inc., Irvine, CA
  • Scott M Whitcup
    Allergan, Inc., Irvine, CA
  • Footnotes
    Commercial Relationships Young Hee Yoon, Allergan, Inc. (C), Allergan, Inc. (R); David Boyer, Allergan, Inc. (C), Allergan, Inc. (F), Allergan, Inc. (R); Rubens Belfort, Jr., Allergan, Inc. (C), Allergan, Inc. (F), Allergan, Inc. (R); Francesco Bandello, Allergan, Inc. (C), Allergan, Inc. (R); Raj Maturi, Allergan, Inc. (C); Albert Augustin, Allergan, Inc. (F), Allergan, Inc. (R); Xiao-Yan Li, Allergan, Inc. (E); Harry Cui, Allergan, Inc. (E); Yehia Hashad, Allergan, Inc. (E); Scott Whitcup, Allergan, Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1779. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Young Hee Yoon, David S Boyer, Rubens Belfort, Jr., Francesco Bandello, Raj K Maturi, Albert J Augustin, Xiao-Yan Li, Harry Cui, Yehia Hashad, Scott M Whitcup, ; Long-term Efficacy and Safety of Dexamethasone Intravitreal Implant in Phakic and Pseudophakic Eyes with Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1779.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the efficacy and safety of dexamethasone intravitreal implant (Ozurdex, DEX implant) 0.7 mg and 0.35 mg for treatment of diabetic macular edema (DME) in phakic and pseudophakic eyes.

Methods: Subgroup analysis of pooled data from two 3-year, randomized, multicenter, masked, sham-controlled, phase III clinical trials with identical protocols. Patients (n=1048) were randomized in a 1:1:1 ratio to treatment with DEX implant 0.7 mg, DEX implant 0.35 mg, or sham procedure in the study eye. Patients who met retreatment eligibility criteria could be retreated no more often than every 6 months. The primary endpoint for the United States FDA was achievement of ≥15-letter improvement in BCVA from baseline at study end in the intent-to-treat population with last-observation-carried-forward for missing values.

Results: Baseline lens status in the study eye was phakic in 773 (73.8%) patients and pseudophakic in 275 (26.2%) patients. The percentage of patients with ≥15-letter improvement in BCVA from baseline at study end in the DEX implant 0.7 mg, DEX implant 0.35 mg, and sham groups, respectively, was 22.2%, 18.4%, and 12.0% overall (P≤0.018 for DEX implant 0.7 and 0.35 mg vs sham); 21.9%, 19.3%, and 12.4% among baseline phakic patients (P≤0.035 for DEX implant 0.7 and 0.35 mg vs sham); and 23.3%, 15.9%, and 10.9% among baseline pseudophakic patients (P=0.024 for DEX implant 0.7 mg vs sham). Mean average reduction in CRT from baseline during the study (area-under-the-curve approach) was greater with DEX implant 0.7 and 0.35 mg than sham in both baseline phakic patients (-104.9, -104.8, and -38.3 µm; P<0.001) and baseline pseudophakic patients (-131.8, -117.1, and -50.8 µm; P<0.001). Rates of cataract-related adverse events in baseline phakic patients were 67.9%, 64.1%, and 20.4%. Only 1 (0.3%) patient treated with DEX implant 0.7 mg and 1 (0.3%) treated with DEX implant 0.35 mg underwent glaucoma incisional surgery for steroid-induced intraocular pressure increases.

Conclusions: With an average of only 4-5 injections over 3 years, DEX implant 0.7 mg and 0.35 mg provided clinically significant improvement in BCVA and reduction in CRT in phakic as well as pseudophakic eyes. The safety profile was favorable.

Keywords: 499 diabetic retinopathy • 487 corticosteroids • 505 edema  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×